No Data
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Intrinsic Value Is Potentially 62% Above Its Share Price
CICC Starts Jiangsu Sinopep-Allsino Biopharmaceutical at Outperform With 88 Yuan Price Target
Juno Biomedical (688076.SH): The actual controlling shareholder proposes a mid-term dividend.
On July 17th, Gelunhui reported that Notai Biological (688076.SH) received a letter from its controlling shareholder and actual controller, Mr. Zhao Dezhong, proposing the implementation of mid-term dividends for Jiangsu Notai Ausino Biopharmaceutical Co., Ltd. in 2024. Based on comprehensive considerations such as confidence in the company's long-term development, financial prospects, shareholder interests, etc., it promotes all shareholders to share the fruits of the company's operations and development, and effectively protects the interests of the broad investors. Mr. Zhao Dezhong, the controlling shareholder and actual controller of the company, proposed that the company's board of directors should as soon as possible, within the scope of authorization by the shareholders' meeting, implement the mid-term dividend after the conditions for it have been met.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s SHSE:688076) Stock?
Sinopep-Allsino Biopharmaceutical's Plant Passes Regulatory Inspection
Nuocheng Bio (688076.SH): the new oral solid preparation workshop and hard capsule production line passed the pharmaceutical GMP compliance inspection.
Notech Biotechnology (688076.SH) announced that its 203 workshop at the China Medicine Port plant has been inspected for compliance with FDA/EM...
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%No Data
